American Hospital Association December 4, 2024

The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex Pharmaceuticals (manufacturer of Casgevy) will participate in its Cell and Gene Therapy Access Model. The voluntary model will test whether a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies improves Medicaid beneficiaries’ health outcomes, broadens access to innovative...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, CMS, Govt Agencies, Payment Models, Pharma / Biotech, Value Based
Related Articles:
MedPAC Says Agents Make More Money Enrolling Clients in Medicare Advantage
Hospital at Home: A Glimpse at Acute Care in 2050
Social Needs Guidance for Medicaid Taken Down by CMS
Mark Farrah Associates Analyzed the 2023 Medical Loss Ratio and Rebates Results
CMS issues Stark law guidance for physician-owned hospital

Share This Article